Document Detail


Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis.
MedLine Citation:
PMID:  8172205     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nutrients rich in omega-3 fatty acids (fish oil and flaxseed) have the potential to abrogate inflammatory and atherosclerotic mechanisms known to be involved in the pathogenesis of vascular damage of systemic lupus erythematosus nephritis. Fish oil dietary supplementation decreases proteinuria and preserves renal morphology in the NZB/NZW, BXSB, and MRL/lpr mouse models of lupus nephritis and decreases mortality in the NZB/NZW and BXSB models. The anti-inflammatory and anti-atherosclerotic potential, coupled with the animal experimental data, encouraged us to carry out a dosing study of low (6 g) and higher (18 g) doses of fish oil (MaxEPA) therapy in human lupus nephritis. At the lower dose, the fish oil inhibited inflammatory mechanisms; at the higher dose, it altered both the inflammatory and atherosclerotic mechanisms. This led to a double-blind cross-over study of fish oil therapy in 26 patients with lupus nephritis followed for 2 years 10 weeks. The fish oil dietary supplementation had no significant effect on proteinuria, isotope glomerular filration rate, disease activity index, or steroid consumption. However, it did have a significant effect on lipid levels. The cross-over design suffered carryover effects (even with a 10-week wash-out period) and placebo effects of the olive oil, which created a risk of type II error. Our interest in omega-3 fatty acids led us to assess the effects of dietary supplementation with flaxseed. Not only is the flaxseed a major source of alpha-linolenic acid but it is also the richest natural source of lignan, a natural platelet-activating factor receptor antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
W F Clark; A Parbtani
Related Documents :
19833185 - Phytochemical investigation and medicinal evaluation of fixed oil of balanites aegyptia...
16960355 - Distribution and metabolism of dihomo-gamma-linolenic acid (dgla, 20:3n-6) by oral supp...
14759155 - Incorporation and stabilization of omega-3 fatty acids in surimi made from cod, gadus m...
3977835 - Chain-shortening of erucic acid and microperoxisomal beta-oxidation in rat small intest...
10464915 - Improved radioiodination of 1,2-dipalmitoyl-3-ippa via a tributyltin intermediate.
18826235 - Copper iodide-catalyzed cyclization of (z)-chalcogenoenynes.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  23     ISSN:  0272-6386     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  1994 May 
Date Detail:
Created Date:  1994-05-27     Completed Date:  1994-05-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  644-7     Citation Subset:  IM    
Affiliation:
Division of Nephrology, Victoria Hospital, London, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Disease Models, Animal
Double-Blind Method
Fatty Acids, Omega-3 / administration & dosage,  therapeutic use*
Female
Humans
Lupus Nephritis / diet therapy,  drug therapy*
Mice
Mice, Inbred Strains
Seeds
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fatty Acids, Omega-3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diuretic drugs and the treatment of edema: from clinic to bench and back again.
Next Document:  Essential fatty acid deficiency profiles in idiopathic immunoglobulin A nephropathy.